{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_14320", "batch_size": 200, "batch_pos": 162, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "'addressing infectious disease outbreaks' is neutral.", "method": "llm_batch", "batch_id": "batch_2_9228", "batch_size": 200, "batch_pos": 127, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "No moderate verb from the approved list is present.", "method": "llm_batch", "batch_id": "batch_3_11468", "batch_size": 200, "batch_pos": 65, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "The segment is a statement, not a question.", "method": "llm_batch", "batch_id": "batch_4_6080", "batch_size": 200, "batch_pos": 51, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "Reports advantages of technology, not explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_21500", "batch_size": 200, "batch_pos": 44, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser combined with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_11356", "batch_size": 200, "batch_pos": 196, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "Segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_20452", "batch_size": 200, "batch_pos": 184, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "The segment states 'mRNA vaccine technology offers advantages', describing the advantages of a technology used for vaccine development/production.", "method": "llm_batch", "batch_id": "batch_8_16560", "batch_size": 200, "batch_pos": 161, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
